Barrington Research Maintains Outperform on Imax, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst James Goss maintains an Outperform rating on Imax and raises the price target from $24 to $28.
November 01, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barrington Research has reaffirmed its Outperform rating on Imax and increased the price target from $24 to $28, indicating a positive outlook.
The reaffirmation of the Outperform rating and the increase in the price target from $24 to $28 by Barrington Research suggests a positive outlook for Imax. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100